The US Food and Drug Administration (FDA) has approved the first drug, resmetirom, for metabolic dysfunction-associated steatohepatitis (MASH), but much work remains for the industry, practitioners and health systems so that this approval will benefit all patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rinella, M. E. et al. Ann. Hepatol. 29, 101133 (2023).
Younossi, Z. M. et al. Hepatology 77, 1335 (2023).
Elizabeth, L. Y. & Schwimmer, J. B. Clin. Liver Dis. 17, 196 (2021).
Harrison, S. A., Allen, A. M., Dubourg, J., Noureddin, M. & Alkhouri, N. Nat. Med. 29, 562–573 (2023).
US Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. FDA https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease (2024).
Harrison, S. A. et al. Nat. Med. 29, 2919–2928 (2023).
Cusi, K. Endocr. Pract. 28, 528–562 (2022).
Gilmore, A. B. et al. Lancet 401, 1194–1213 (2023).
Younossi, Z. M., Zelber-Sagi, S., Henry, L. & Gerber, L. H. Nat. Rev. Gastroenterol. Hepatol. 20, 708–722 (2023).
Asquith, E., Bould, K., Catling, J., Day, E. & Holt, A. BMC Gastroenterol. 23, 306 (2023).
Cannon, C. E. Int. J. Environ. Res. Public Health 17, 2303 (2020).
Lazarus, J. V. et al. Hepatology 79, 502–523 (2024).
Lazarus, J. V. et al. J. Hepatol. 79, 618–634 (2023).
Ratziu, V. & Charlton, M. J. Hepatol. 78, 1073–1079 (2023).
Lewis, K. H., Moore, J. B. & Ard, J. D. Obesity 32, 237–239 (2023).
Acknowledgements
J.V.L., D.I.W., H.E.M. and C.J.K. acknowledge support to ISGlobal from grant CEX2018-000806-S, funded by MCIN/AEI/10.13039/501100011033, and the ‘Generalitat de Catalunya,’ through the CERCA program, outside of the submitted work.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.V.L. acknowledges grants to ISGlobal from AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Madrigal, MSD, Novo Nordisk, Pfizer and Roche Diagnostics; consulting fees from Echosens, NovoVax, GSK, Novo Nordisk and Pfizer; and payment or honoraria for lectures from AbbVie, Echosens, Gilead Sciences, Janssen, Moderna, MSD, Novo Nordisk and Pfizer, outside of the submitted work. Z.M.Y. acknowledges consulting fees from Intercept, Cymabay, Boehringer Ingelheim, Bristol Myers Squibb, GSK, NovoNordisk, AstraZeneca, Siemens, Madridgal, Merck, Ipsen and Abbott, outside of the submitted work. M.B.B. acknowledges grants or contracts to her institution from the NIH, the CDC/NIOSH, Pfizer, the Kinetix Group and Histoindex; consulting fees from Kinetix, Madrigal, Pfizer, Fibronostics, NOVO Nordisk, GSK and Merck; and payment or honoraria from Madrigal, NOVO Nordisk and GSK, outside of the submitted work. M.B. acknowledges grants to the Fatty Liver Alliance from Madrigal Pharmaceuticals, Inventiva, Regeneron, Hoffmann-La Roche, the Global Liver Institute, Siemens Healthineers, Aegle Medical, Pfizer, the Canadian Liver Foundation, Altimmune, KNS Canada, Sentrex Health Solutions, Novo Nordisk, Intercept Pharmaceuticals and the Canadian Institute of Health Research; consulting fees from Hoffmann-La Roche, Madrigal Pharmaceuticals and the Global Liver Institute; payment or honoraria from Inventiva and MCI (grant to the Fatty Liver Alliance); and support for attending meetings and/or travel from Regeneron, Arizona Liver Health and the Liver Forum, outside of the submitted work. P.N.B. acknowledges consulting fees from Resolution Therapeutics and payment or honoraria for lectures from Takeda, outside of the submitted work. D.I.W., H.E.M., C.J.K. and N.C. declare no competing interests.
Rights and permissions
About this article
Cite this article
Lazarus, J.V., Ivancovsky Wajcman, D., Mark, H.E. et al. Opportunities and challenges following approval of resmetirom for MASH liver disease. Nat Med (2024). https://doi.org/10.1038/s41591-024-02958-z
Published:
DOI: https://doi.org/10.1038/s41591-024-02958-z